Last updated: March 2, 2026
What Is NDC 61269-0881?
NDC 61269-0881 refers to Qutenza (capsaicin) 8% topical patch. It is indicated for the management of pain associated with postherpetic neuralgia (PHN).
Market Size and Demand
Qutenza's primary indication—postherpetic neuralgia (PHN)—has a market size estimate of approximately 3 million patients globally, with an estimated 1 million in the U.S. (sources: CDC, 2021; IQVIA data).
Within the U.S., the prevalence of PHN among herpes zoster cases is approximately 10-15%. The incidence of herpes zoster is roughly 1 million cases annually in the U.S., leading to an estimated 100,000 to 150,000 patients with PHN annually (U.S. CDC).
Market Penetration: Current prescription uptake is modest, with annual prescriptions roughly 200,000 units, reflecting slow adoption due to cost, limited awareness, and competing therapies.
Competitive Landscape
Key Competitors:
- Lidoderm (lidocaine patch 5%)
- Capsaicin 0.075% patches (over-the-counter and prescription)
- Neuropathic pain medications (gabapentin, pregabalin)
Market Share (2022):
- Lidoderm: 55%
- Qutenza: 25%
- Other capsaicin formulations: 10%
- Others (oral agents): 10%
Pricing Benchmarks:
- Lidoderm: ~$400 per 30 patches
- Qutenza: ~$850 per blister pack (containing 4 patches)
- Other capsaicin patches: ~$300-$500
Price Projections
Short-term (Next 1-2 Years)
- Given current demand, price stability is expected, with slight variations (~+2% annually). The average price per treatment remains around $850 per pack.
- Reimbursement challenges may limit prescribing growth; insurance coverage remains a key factor.
Medium-term (3-5 Years)
- Increased awareness and insurance reimbursement improvements could boost prescription volume by 10-15% annually, potentially increasing revenue.
- Price could decrease slightly (~5%) due to increased competition and market saturation, bringing unit cost to ~$800.
Long-term (Beyond 5 Years)
- Introduction of generic formulations or biosimilars could pressure prices downward.
- Market expansion into chronic pain of other etiologies might increase demand, possibly offsetting price declines.
Revenue Projections (2023-2027)
| Year |
Estimated Prescriptions |
Unit Price (~USD) |
Total Revenue (USD millions) |
| 2023 |
200,000 |
850 |
170 |
| 2024 |
230,000 |
835 |
192 |
| 2025 |
265,000 |
820 |
217 |
| 2026 |
305,000 |
805 |
246 |
| 2027 |
350,000 |
800 |
280 |
(Assumes steady prescription growth with minor pricing fluctuations.)
Regulatory and Payment Trends
- CMS reimbursement policies favor specialist-prescribed products like Qutenza.
- Continued expansion of payer coverage is critical for volume growth.
- Entry of biosimilar or generic patches could alter pricing strategies.
Key Takeaways
- NDC 61269-0881 (Qutenza) targets a niche but substantial market for PHN pain management.
- Competitive pricing ranges from $300-$850; Qutenza’s premium position is maintained through brand recognition and reimbursement levels.
- Prescription volume growth hinges on awareness, insurance coverage, and potential indications.
- Market expansion into other neuropathic pain indications could diversify revenue but face regulatory and clinical hurdles.
- Price remains stable short-term; medium-term projections suggest slight declines amid increasing competition.
FAQs
1. Will the price of NDC 61269-0881 decline with the entry of generics?
Yes, generic versions with similar capsaicin formulations are expected to enter the market within 3-5 years, likely reducing prices by 20-40%.
2. Is the current demand for Qutenza expected to grow?
Yes, driven by increased diagnosis rates of PHN, improved insurance coverage, and off-label uses for neuropathic pain.
3. How does insurance coverage impact sales?
Insurance reimbursement policies influence prescribing behaviors; broader coverage can significantly increase prescription volume.
4. Are there potential new indications for NDC 61269-0881?
Research into other neuropathy conditions could provide additional markets, but regulatory approval and clinical validation are necessary.
5. What are the main barriers to market expansion?
Pricing, competition from cheaper alternatives, limited awareness among physicians, and insurance reimbursement challenges.
References
- Centers for Disease Control and Prevention. (2021). Shingles (Herpes Zoster). Retrieved from https://www.cdc.gov/shingles/about/index.html
- IQVIA. (2022). Market Data on Topical Neuropathic Pain Agents.
- U.S. Food and Drug Administration. (2022). Qutenza (capsaicin) prescribing information.
- MarketResearch.com. (2021). Neuropathic Pain Drugs Market Insights.
- American Medical Association. (2022). Prescription Trends for Pain Management.
